Compare YieldMax COIN Option Income Strategy ETF (CONY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs ResMed Inc. — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $19.87, while ResMed Inc. trades at $195.15 (market cap $28.00B). The key difference: ResMed Inc. pays a 1.24% dividend while YieldMax COIN Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| CONY | RMD | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $103.20 | $293.73 |
52-Week Low | $18.43 | $182.82 |
Market Cap | — | $28.00B |
Enterprise Value | — | $27.18B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.
The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
